From the Research
Alflutop should be used as a first-line treatment for osteoarthritis due to its efficacy in relieving pain, improving joint function, and modifying the disease structure, as demonstrated in the most recent and highest quality study 1. The standard regimen for Alflutop involves intramuscular injections of 1 ml daily for 20 days, or 1-2 ml injections directly into affected joints 1-3 times weekly. Some key points to consider when using Alflutop include:
- The medication contains bioactive small fish concentrate with glycosaminoglycans that help repair cartilage, reduce inflammation, and improve joint function.
- Alflutop works by stimulating chondrocyte metabolism and synthesis of cartilage matrix components while inhibiting enzymes that break down cartilage.
- Patients may experience mild side effects including injection site reactions or allergic responses.
- This medication is more commonly used in Eastern European countries and may not be approved in all regions.
- Before starting treatment, patients should consult with their healthcare provider to determine if Alflutop is appropriate for their specific condition and to establish the optimal dosing schedule. The use of Alflutop has been shown to be effective in various studies, including a study published in 2004 2 which demonstrated its efficacy in relieving pain and improving joint function in patients with osteoarthritis. Another study published in 2011 3 showed that Alflutop can be used in combination with other treatments, such as peloid applications, to achieve better results. Additionally, a study published in 2005 4 demonstrated the efficacy of Alflutop in the local therapy of shoulder periarthritis. However, it is essential to note that the most recent and highest quality study 1 should be prioritized when making treatment decisions, as it provides the most up-to-date and reliable evidence on the efficacy and safety of Alflutop.